Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | REN | P00797 | 12/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496474 | 0.92 | KLK5 (0.61) | KLK5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL496475 | 0.92 | KLK5 (0.61) | KLK5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL496314 | 0.90 | KLK5 (0.63) | KLK5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL495900 | 0.87 | ADORA3 (0.64) | KLK5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL495899 | 0.87 | ADORA3 (0.64) | KLK5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL496156 | 0.85 | KLK5 (0.61) | KLK5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL496157 | 0.85 | KLK5 (0.61) | KLK5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL496310 | 0.83 | GPR119 (0.43) | KLK5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL495742 | 0.83 | KLK5 (0.62) | KLK5ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL9581380 | 0.82 | KLK5 (0.59) | KLK5ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910317-B1 | 1-AMINO LINKED COMPOUNDS | LILLY CO ELI (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8106090-B2 | Antidiabetic agents; prevent of non-insulin dependent diabetes | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-20080207735-A1 | 1-Amino Linked Compounds | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207735-A1 | 1-Amino Linked Compounds | DPP4, DPP3, DPP9 | KLK5 3927/4885ADORA3 223/4885ADORA2A 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.